Recent developments in Alzheimer's disease therapeutics MS Rafii, PS Aisen BMC medicine 7 (1), 1-4, 2009 | 232 | 2009 |
A phase II trial of huperzine A in mild to moderate Alzheimer disease MS Rafii, S Walsh, JT Little, K Behan, B Reynolds, C Ward, S Jin, ... Neurology 76 (16), 1389-1394, 2011 | 185 | 2011 |
Agrin and microvascular damage in Alzheimer’s disease TM Berzin, BD Zipser, MS Rafii, V Kuo—Leblanc, GD Yancopouloš, ... Neurobiology of aging 21 (2), 349-355, 2000 | 178 | 2000 |
A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease MS Rafii, TL Baumann, RAE Bakay, JM Ostrove, J Siffert, AS Fleisher, ... Alzheimer's & Dementia 10 (5), 571-581, 2014 | 147 | 2014 |
High-throughput, fully-automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment S Kovacevic, MS Rafii, JB Brewer Alzheimer disease and associated disorders 23 (2), 139, 2009 | 115 | 2009 |
Agrin in Alzheimer’s disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma JE Donahue, TM Berzin, MS Rafii, DJ Glass, GD Yancopoulos, JR Fallon, ... Proceedings of the National Academy of Sciences 96 (11), 6468-6472, 1999 | 106 | 1999 |
Advances in Alzheimer’s disease drug development MS Rafii, PS Aisen BMC medicine 13 (1), 1-7, 2015 | 92 | 2015 |
A phase 3 trial of IV immunoglobulin for Alzheimer disease NR Relkin, RG Thomas, RA Rissman, JB Brewer, MS Rafii, CH Van Dyck, ... Neurology 88 (18), 1768-1775, 2017 | 91 | 2017 |
The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual … JA Moran, MS Rafii, SM Keller, BK Singh, MP Janicki Mayo Clinic Proceedings 88 (8), 831-840, 2013 | 80 | 2013 |
Evidence for a postnatal doubling of neuron number in the developing human cerebral cortex between 15 months and 6 years WR Shankle, BH Landing, MS Rafii, A Schiano, JM Chen, J Hara Journal of Theoretical Biology 191 (2), 115-140, 1998 | 77 | 1998 |
Approximate doubling of numbers of neurons in postnatal human cerebral cortex and in 35 specific cytoarchitectural areas from birth to 72 months WR Shankle, MS Rafii, BH Landing, JH Fallon Pediatric and developmental pathology 2 (3), 244-259, 1999 | 73 | 1999 |
Biglycan binds to α‐and γ‐sarcoglycan and regulates their expression during development MS Rafii, H Hagiwara, ML Mercado, NS Seo, T Xu, T Dugan, RT Owens, ... Journal of cellular physiology 209 (2), 439-447, 2006 | 61 | 2006 |
Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS ML Mercado, AR Amenta, H Hagiwara, MS Rafii, BE Lechner, RT Owens, ... The FASEB journal 20 (10), 1724-1726, 2006 | 60 | 2006 |
Adeno-associated viral vector (serotype 2)–nerve growth factor for patients with alzheimer disease: a randomized clinical trial MS Rafii, MH Tuszynski, RG Thomas, D Barba, JB Brewer, RA Rissman, ... JAMA neurology 75 (7), 834-841, 2018 | 59 | 2018 |
Down's syndrome and Alzheimer's disease: towards secondary prevention S Ness, M Rafii, P Aisen, M Krams, W Silverman, H Manji Nature Reviews Drug Discovery 11 (9), 655-656, 2012 | 59 | 2012 |
The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome M Rafii, H Wishnek, J Brewer, M Donohue, S Ness, W Mobley, P Aisen, ... Frontiers in behavioral neuroscience 9, 239, 2015 | 56 | 2015 |
PET imaging of tau pathology and relationship to amyloid, longitudinal MRI, and cognitive change in Down syndrome: results from the Down Syndrome Biomarker Initiative (DSBI) MS Rafii, AS Lukic, RD Andrews, J Brewer, RA Rissman, SC Strother, ... Journal of Alzheimer's Disease 60 (2), 439-450, 2017 | 47 | 2017 |
Down syndrome SE Antonarakis, BG Skotko, MS Rafii, A Strydom, SE Pape, DW Bianchi, ... Nature Reviews Disease Primers 6 (1), 1-20, 2020 | 39 | 2020 |
Outcome measures for clinical trials in Down syndrome AJ Esbensen, SR Hooper, D Fidler, SL Hartley, J Edgin, XL d'Ardhuy, ... American journal on intellectual and developmental disabilities 122 (3), 247-281, 2017 | 39 | 2017 |
Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal‐dominant Alzheimer's disease M Carmona‐Iragui, M Balasa, B Benejam, D Alcolea, S Fernández, ... Alzheimer's & Dementia 13 (11), 1251-1260, 2017 | 34 | 2017 |